Fig 1: Gene expression profiles demonstrating IL32 levels in the GEO datasets used in the study. The plot represents the normalized IL32 gene expression levels observed for the Affymetrix 203826_s_at probeset in the (a) GDS2250 clinical samples (b) GDS1329 clinical samples (c) GSE34211 cell lines and (d) GSE12777 cell line datasets. The dashed lines are used to group the particular sample types. The normalized gene expression levels were averaged to demonstrate differences (i.e., mean) in IL32 levels between the various sample types. The mean and standard deviations values were also determined (using Excel).
Fig 2: IHC analysis of IL32 levels in TMA. CD31 and IL32 protein expression was determined in various types of breast tissues. TNBC demonstrating (a) positive IL32 expression and (b) CD31 control expression. Non-TNBC demonstrating (c) positive IL32 expression and (d) CD31 control expression. Non-TNBC demonstrating (e) negative IL32 expression and (f) CD31 control expression. Invasive ductal or lobular carcinoma demonstrating (g) positive IL32 expression and (h) CD31 control expression. Bar = 50uM.
Fig 3: Analysis showing overexpression of IL32 gene expression in MDA MB231 (TNBC) compared to MCF7 (receptor positive). (a) PCR analysis of IL32 transcript in MCF7 compared to MDA MB231. MRPL19 was used as the endogenous control gene (b) Western analysis of IL32 protein in MCF7, MDA MB231, Positive control protein and negative control. Actin gene was used as endogenous control.
Supplier Page from Novus Biologicals, a Bio-Techne Brand for IL-32 Overexpression Lysate